Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

80.61USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$80.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,132
52-wk High
$85.66
52-wk Low
$48.94

Select another date:

Wed, May 16 2018

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE

BRIEF-Eagle Pharmaceuticals Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.53

* EAGLE PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2018 RESULTS

BRIEF-Eagle Pharmaceuticals Says CEO Scott Tarriff's 2017 Total Compensation Was $8.04 Mln

* EAGLE PHARMACEUTICALS INC SAYS CEO SCOTT TARRIFF'S 2017 TOTAL COMPENSATION WAS $8.04 MILLION VERSUS $7.15 MILLION IN 2016 – SEC FILING Source : https://bit.ly/2HK04hV Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals’ Vasopressin ANDA Accepted For Filing By The FDA

* EAGLE PHARMACEUTICALS’ VASOPRESSIN ANDA ACCEPTED FOR FILING BY THE FDA

BRIEF-Eagle Pharmaceuticals - Announced Co's Eagle Biologics Division Has Been Issued A New Patent

* EAGLE PHARMACEUTICALS - ANNOUNCED CO'S EAGLE BIOLOGICS DIVISION HAS BEEN ISSUED A NEW PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Eagle Pharmaceuticals Reports Q4 EPS Of $0.58

* EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

Select another date: